Here are six takeaways:
1. The analyst firm also gave the company a $58 post-split target price, which is $3 higher than the highest target price on Wall Street.
2. Ultimately, Argus gave Integra a nearly 40 percent upside.
3. The analyst noted the company’s strong growth potential as well as ability to act on acquisition and merger moves.
4. Integra acquired Derma Sciences in March, and made a binding offer to acquire Johnson & Johnson Codman Neurosurgery in the first quarter of 2017. Argus predicted these acquisitions could result in an additional $400 million in annual sales.
5. Argus also kept a close eye on Integra’s product launches in the first quarter of this year, including a neurosurgery tissue ablation system and a reverse-shoulder implant.
6. The firm pointed to tissue regeneration products and neurosurgery instruments as driving product lines for Integra.
More articles on devices:
MicroPort Orthopedics launches system to help TKR patients — 5 takeaways
Integra expands credit facility to include $700M term loan — 4 details
Cutting mortality risk by shining light on osteoporosis & vertebral compression fracture treatment
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
